These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Scleromyxedema: successful treatment with thalidomide in two patients. Amini-Adle M; Thieulent N; Dalle S; Balme B; Thomas L Dermatology; 2007; 214(1):58-60. PubMed ID: 17191049 [TBL] [Abstract][Full Text] [Related]
29. [Arndt-Gottron scleromyxedema. Case report and review of therapeutic possibilities]. Schirren CG; Betke M; Eckert F; Przybilla B Hautarzt; 1992 Mar; 43(3):152-7. PubMed ID: 1577603 [TBL] [Abstract][Full Text] [Related]
31. Scleromyxoedema (lichen myxoedematosus) associated with a paraprotein, IgG 1 of type kappa. Lai a Fat RF; Suurmond D; Rádl J; van Furth R Br J Dermatol; 1973 Feb; 88(2):107-16. PubMed ID: 4574768 [No Abstract] [Full Text] [Related]
32. Scleromyxedema, a positive effect with thalidomide. Jacob SE; Fien S; Kerdel FA Dermatology; 2006; 213(2):150-2. PubMed ID: 16902294 [TBL] [Abstract][Full Text] [Related]
33. Scleromyxedema: treatment with interferon alfa. Tschen JA; Chang JR J Am Acad Dermatol; 1999 Feb; 40(2 Pt 2):303-7. PubMed ID: 10025854 [TBL] [Abstract][Full Text] [Related]
34. [Scleromyxedema therapy with isotretinoin]. Lominska-Lasota K; Rosen-Uzelac G; Reichl W; Bauer R Z Hautkr; 1988 Feb; 63(2):137-8, 141. PubMed ID: 3163867 [TBL] [Abstract][Full Text] [Related]
35. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Efthimiou P; Blanco M Semin Arthritis Rheum; 2008 Dec; 38(3):188-94. PubMed ID: 18221985 [TBL] [Abstract][Full Text] [Related]
36. [Scleromyxedema-type papular mucinosis]. DEGOS R Ann Dermatol Syphiligr (Paris); 1959; 86():486-94. PubMed ID: 13815426 [No Abstract] [Full Text] [Related]
37. Scleromyxedema is a scleroderma-like disorder and not a coexistance of scleroderma with papular mucinosis. Jablonska S; Blaszczyk M Eur J Dermatol; 1999; 9(7):551-4. PubMed ID: 10523735 [TBL] [Abstract][Full Text] [Related]
38. [Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy]. Krajnc I; Vizjak A; Hvala A; Jurcic V; Rozman B Acta Med Austriaca; 1998; 25(3):109-12. PubMed ID: 9816405 [TBL] [Abstract][Full Text] [Related]
39. Scleromyxedema associated with arthritis and myopathy: a case report. Espinosa A; De Miguel E; Morales C; Fonseca E; Gijón-Baños J Clin Exp Rheumatol; 1993; 11(5):545-7. PubMed ID: 8275591 [TBL] [Abstract][Full Text] [Related]
40. Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases. Rongioletti F; Merlo G; Carli C; Cribier B; Metze D; Calonje E; Kempf W; Stefanato CM; Marinho E; Kanitakis J J Am Acad Dermatol; 2016 Jun; 74(6):1194-200. PubMed ID: 26897387 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]